To determine whether IL-15 overexpression-mediated activation of the AKT-mTORC1 pathway is responsible for the upregulation of vimentin expression, we used LY294002 and rapamycin to inhibit AKT and mTORC1 activity, respectively, in cultured IL-15-overexpressing tumor cells. The gene discussed is VIM; the disease is neoplasm.